On February 25, 2025, N2Off Inc. signed an agreement to acquire MitoCareX Bio Ltd., making it a wholly-owned subsidiary, for $700,000 and issuing shares representing 15.50%, 7.75%, and 16.75% of the company to the sellers. The deal includes future financing commitments and milestone-based stock issuances totaling up to 25% of the company's capital stock.